Physician profile
Kseniya Kobets
NPI 1912296674
$2,326.50
in general payments reported to CMS, 2019-2025
29 companies · $374 in 2025
The $374 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,209 · 2020: $163 · 2021: $19.77 · 2022: $89.57 · 2023: $353 · 2024: $119 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $401.19 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $386.70 | 2022-2025 | Absorica Ld, Winlevi |
| Abbvie INC. | $222.40 | 2019-2025 | |
| Pfizer INC. | $213.60 | 2019-2020 | |
| Allergan, INC. | $150.00 | 2019 | |
| Journey Medical Corporation | $134.30 | 2019 | |
| Almirall LLC | $112.97 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $82.37 | 2019-2020 | |
| Biofrontera INC. | $76.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.99 | 2019-2023 | |
| Novum Pharma, LLC | $59.12 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $41.26 | 2022 | |
| Prugen, INC. Pharmaceuticals | $34.06 | 2019 | |
| Ionis Pharmaceuticals, INC. | $33.42 | 2025 | Dawnzera |
| Apyx Medical Corporation | $31.64 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $30.73 | 2023 | Haegarda |
| Dermavant Sciences, INC. | $29.90 | 2022 | |
| Genzyme Corporation | $29.84 | 2019 | |
| Aurinia Pharma U.S., INC. | $29.47 | 2023 | Lupkynis |
| Glenmark Therapeutics INC. | $29.00 | 2019 | |
| Epi Health, LLC | $18.87 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2025 | Cuvitru |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.16 | 2024 | Cabtreo |
| Amgen INC. | $14.42 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $14.42 | 2019 | |
| Dermira, INC. | $14.29 | 2019 | |
| Leo Pharma INC. | $14.12 | 2019 | |
| Vyne Pharmaceuticals INC. | $14.10 | 2020 | |
| Celgene Corporation | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kseniya Kobets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.